Niox Group Plc (Niox Group) formerly Circassia Group Plc (Circassia), is primarily engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for asthma. It provides market-leading NIOX products used globally by physicians to improve asthma diagnosis and management. The company operates in the healthcare industry, addressing significant issues such as asthma and COPD, with 340 million asthma sufferers worldwide and 380 million people living with COPD.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Niox continued to invest in advancing its next-generation FeNO devices during 2025, including the successful launch of the NIOX PRO and the commencement of development of the NIOX MyNO, a home-use FeNO device. The company focused on innovation and expanding access to FeNO testing. The R&D unit of Niox Group Plc is responsible for regulatory, quality assurance, medical affairs, and device development activities. This unit manages the company's R&D activities, including the development of NIOX products and the investment in new device innovations. in FY2025, the company incurred an expense of GBP2.6 million, which stood at 5.3% of its total revenue.